Fluorescently labeled DNA probes bind complementary target sequences, so microscopy converts hybridization into visible signal patterns. The number and arrangement of signals can indicate whether a target region is present in an expected copy number or shows an abnormal pattern. This makes probe choice central to interpreting a clinical assay.
Interphase FISH can analyze nondividing cells, avoiding the requirement for metaphase chromosomes when those chromosomes are unavailable. That capability matters because fixed interphase nuclei can be examined directly, including in uncultured material. The result is rapid genetic information from specimens that might not yield a metaphase preparation, supporting timely clinical testing.
Signal number, position, and pattern are complementary interpretive features. A probe set can reveal changes such as gene amplification, deletion, rearrangement, or aneuploidy by showing abnormal fluorescence arrangements relative to the targeted sequences. Because each probe addresses a specific DNA region, interpretation remains tied to the genomic alteration being investigated.
The core workflow starts with fixed interphase nuclei, followed by exposure to fluorescently labeled DNA probes that can hybridize with complementary sequences. Microscopy then records the resulting signals and their number, position, or pattern. Because the assay examines nuclei without requiring metaphase chromosomes, it can provide genetic information from uncultured cells when a rapid result is needed.
In tumor samples, the assay can be directed toward genomic changes relevant to the specimen, including gene amplification, deletion, rearrangement, or aneuploidy. The resulting signal pattern supplies genetic information for diagnostic testing and can help characterize disease-related changes. Its ability to work with uncultured material is especially relevant when obtaining a rapid result matters.
In medicine, Interphase FISH can support diagnostic testing, treatment planning, and monitoring of genomic changes in disease. Its value comes from linking a visible fluorescence pattern to a defined DNA target in a clinical specimen. This targeted readout helps organize information about tumor or other clinical samples when a specific abnormality is clinically relevant.